文献速递头颈部肿瘤放疗

局部晚期头颈癌同步放化疗随机III期试验:减量放疗联合紫杉醇/顺铂对比标准放疗联合氟尿嘧啶/顺铂(PacCis试验)

Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial.
PubMed 文献 · Radiother Oncol · 2020-02-07

该多中心III期试验纳入221例III-IVB期头颈部鳞癌患者,随机接受紫杉醇/顺铂同步放化疗(放疗总量63.6 Gy)或氟尿嘧啶/顺铂同步放化疗(放疗总量70.6 Gy)。结果显示两组3年无病生存率和总生存率均无显著差异,减量放疗联合紫杉醇/顺铂方案未优于标准方案。亚组分析提示p16阳性口咽癌或非吸烟者可能从减量放疗中获益。

要点

  • 减量放疗联合紫杉醇/顺铂未显著改善局部晚期头颈癌的3年DFS和OS。
  • p16阳性口咽癌亚组中两组3年DFS和OS无显著差异,但减量放疗可能足够。
  • 紫杉醇/顺铂组3-4级血液学毒性显著降低,但3级感染在氟尿嘧啶/顺铂组更低。

核心结论

  • 减量放疗联合紫杉醇/顺铂方案不优于标准氟尿嘧啶/顺铂同步放化疗。
  • 亚组分析提示减量放疗对p16阳性口咽癌或非吸烟者可能足够。

研究设计与样本

  • 多中心III期随机对照试验,纳入221例III-IVB期头颈部鳞状细胞癌患者,2010至2015年入组。
  • A组接受紫杉醇/顺铂同步放化疗(放疗总量63.6 Gy),B组接受氟尿嘧啶/顺铂同步放化疗(放疗总量70.6 Gy)。
  • 主要终点为3年无病生存率(3y-DFS),中位随访3.7年。

主要发现

  • 氟尿嘧啶/顺铂组与紫杉醇/顺铂组的3y-DFS分别为58.2%和48.4%(HR 0.82,95%CI 0.56-1.21,p=0.52)。
  • 两组3年总生存率分别为64.6%和59.2%(HR 0.82,95%CI 0.54-1.24,p=0.43)。
  • p16阳性口咽癌亚组中,A组与B组的3y-DFS分别为84.6%和83.9%(p=0.653),3y-OS分别为92.3%和83.5%(p=0.76)。
  • A组3-4级血液学毒性显著降低(贫血p=0.01;白细胞减少p=0.003),B组3级感染显著降低(p=0.01)。

关键数值与推荐

  • A组紫杉醇20 mg/m2于第2、5、8、11天及第25、30、33、36天给药,顺铂20 mg/m2于第1-4天及第29-32天给药,放疗总量63.6 Gy。
  • B组氟尿嘧啶600 mg/m2和顺铂20 mg/m2于第1-5天及第29-33天给药,放疗总量70.6 Gy。

临床怎么用

  • 对于局部晚期头颈鳞癌,标准氟尿嘧啶/顺铂同步放化疗仍是参考方案,减量放疗联合紫杉醇/顺铂未显示优效。
  • p16阳性口咽癌或非吸烟患者可考虑减量放疗,但需进一步验证。
  • 选择方案时需权衡血液学毒性与感染风险。

局限性

  • 样本量221例,亚组分析样本量小,结果需谨慎解读。
  • 中位随访3.7年,长期生存数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: This multicenter, phase 3 trial investigates whether the incorporation of concurrent paclitaxel and cisplatin together with a reduced total dose of radiotherapy is superior to standard fluorouracil-cisplatin based CRT. MATERIALS AND METHODS: Patients with SCCHN, stage III-IVB, were randomized to receive paclitaxel/cisplatin (PacCis)-CRT (arm A; paclitaxel 20 mg/m2 on days 2, 5, 8, 11 and 25, 30, 33, 36; cisplatin 20 mg/m2, days 1-4 and 29-32; RT to a total dose of 63.6 Gy) or fluorouracil/cisplatin (CisFU)-CRT (arm B; fluorouracil 600 mg/m2; cisplatin 20 mg/m2, days 1-5 and 29-33; RT: 70.6 Gy). Endpoint was 3-year-disease free survival (3y-DFS). RESULTS: A total of 221 patients were enrolled between 2010 and 2015. With a median follow-up of 3.7 years, 3y-DFS in the CisFU arm and PacCis arm was 58.2% and 48.4%, respectively (HR 0.82, 95% CI 0.56-1.21, p = 0.52). The 3y-OS amounted to 64.6% in the CisFU arm, and to 59.2% in the PacCis arm (HR 0.82, 95% CI 0.54-1.24, p = 0.43). In the subgroup of p16-positive oropharyngeal carcinomas, 3y-DFS and 3y-OS was 84.6% vs 83.9% (p = 0.653), and 92.3% vs. 83.5% (p = 0.76) in arm A and B, respectively. Grade 3-4 hematological toxicities were significantly reduced in arm A (anemia, p = 0.01; leukocytopenia, p = 0.003), whereas grade 3 infections were reduced in arm B (p = 0.01). CONCLUSION: Paclitaxel/cisplatin-CRT with a reduced RT-dose is not superior to standard fluorouracil/cisplatin-CRT. Subgroup analyses indicate that a reduced radiation dose seems to be sufficient for p16+ oropharyngeal cancer or non-smokers. CLINICAL TRIAL INFORMATION: NCT01126216; EudraCT Number 2005-003484-23.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Fietkau R, Hecht M, Hofner B, et al. Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial. Radiother Oncol. 2020. PMID: 32044419. doi:10.1016/j.radonc.2020.01.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。